Skip to main content

Advertisement

SpringerLink
Log in

Ubiquitination in host immune response to human papillomavirus infection

  • Review
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Human papillomavirus (HPV) infection with low-risk or high-risk subtypes is very common. Infection with HPVs is often a major causative factor for the development of cutaneous benign lesions, cervical cancer, and a number of other tumors. The mechanisms of host immunity to prevent and control HPV infection still remain unclear. The importance of ubiquitination (or ubiquitylation) as an intracellular proteasomal-mediated protein degradation pathway, and as an important modulator for the regulation of many fundamental cellular processes has been valued over the last decade. Although the molecular and cellular mechanisms are not completely established, the critical role of ubiquitination in host immune response to HPV infection has become increasingly apparent. This review summarizes current knowledge on the possible role that ubiquitination plays in regulating the host immune response during HPV infection. Targeting the components of the ubiquitin system might offer potential therapeutic strategies for HPV-related diseases in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Andersen MW, Ballal NR, Goldknopf IL, Busch H (1981) Protein A24 lyase activity in nucleoli of thioacetamide-treated rat liver releases histone 2A and ubiquitin from conjugated protein A24. Biochemistry 20(5):1100–1104

    PubMed  CAS  Google Scholar 

  2. Ang XL, Wade Harper J (2005) SCF-mediated protein degradation and cell cycle control. Oncogene 24(17):2860–2870

    PubMed  CAS  Google Scholar 

  3. Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, Mariathasan S, Bouchard D, Wakeham A, Itie A, Le J, Ohashi PS, Sarosi I, Nishina H, Lipkowitz S, Penninger JM (2000) Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403(6766):211–216

    PubMed  CAS  Google Scholar 

  4. Balkwill F (2006) TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25(3):409–416

    PubMed  CAS  Google Scholar 

  5. Beaudenon S, Huibregtse JM (2008) HPV E6, E6AP and cervical cancer. BMC Biochem 9(Suppl 1):S4

    Google Scholar 

  6. Beg AA, Baltimore D (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274(5288):782–784

    PubMed  CAS  Google Scholar 

  7. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Barker PA (2008) cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 30(6):689–700

    PubMed  CAS  Google Scholar 

  8. Beutler B (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430(6996):257–263

    PubMed  CAS  Google Scholar 

  9. Bhoj VG, Chen ZJ (2009) Ubiquitylation in innate and adaptive immunity. Nature 458(7237):430–437

    PubMed  CAS  Google Scholar 

  10. Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214(2):149–160

    PubMed  CAS  Google Scholar 

  11. Call ME, Wucherpfennig KW (2005) The T cell receptor: critical role of the membrane environment in receptor assembly and function. Annu Rev Immunol 23:101–125

    PubMed  CAS  Google Scholar 

  12. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72(9):3666–3670

    PubMed  CAS  Google Scholar 

  13. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin M (2006) The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 124(3):601–613

    PubMed  CAS  Google Scholar 

  14. Chen XZ, Mao XH, Zhu KJ, Jin N, Ye J, Cen JP, Zhou Q, Cheng H (2010) Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells. Arch Dermatol Res 302(1):57–65

    PubMed  CAS  Google Scholar 

  15. Chen ZJ (2005) Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 7(8):758–765

    PubMed  CAS  Google Scholar 

  16. Chen ZJ, Parent L, Maniatis T (1996) Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell 84(6):853–862

    PubMed  CAS  Google Scholar 

  17. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, Jang IK, Gutkind JS, Shevach E, Gu H (2000) Cbl-b regulates the CD28 dependence of T cell activation. Nature 403(6766):216–220

    PubMed  CAS  Google Scholar 

  18. Chuang TH, Ulevitch RJ (2004) Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat Immunol 5(5):495–502

    PubMed  CAS  Google Scholar 

  19. Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79(1):13–21

    PubMed  CAS  Google Scholar 

  20. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324(1):17–27

    PubMed  Google Scholar 

  21. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ (2000) Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103(2):351–361

    PubMed  CAS  Google Scholar 

  22. Dolcet X, Llobet D, Pallares J, Matias-Guiu X (2005) NF-kB in development and progression of human cancer. Virchows Arch 446(5):475–482

    PubMed  CAS  Google Scholar 

  23. Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102(1):33–42

    PubMed  CAS  Google Scholar 

  24. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594):850–854

    PubMed  CAS  Google Scholar 

  25. Duwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U, Darnay BG, Ruland J, Marynen P, Krappmann D (2009) A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol 182(12):7718–7728

    PubMed  Google Scholar 

  26. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ (2006) Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 22(2):245–257

    PubMed  CAS  Google Scholar 

  27. Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D (2009) Clinician’s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 9(6):347–356

    PubMed  CAS  Google Scholar 

  28. Elliott PJ, Zollner TM, Boehncke WH (2003) Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 81(4):235–245

    PubMed  CAS  Google Scholar 

  29. Fahey LM, Raff AB, Da Silva DM, Kast WM (2009) Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol 182(5):2919–2928

    PubMed  CAS  Google Scholar 

  30. Fausch SC, Da Silva DM, Rudolf MP, Kast WM (2002) Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 169(6):3242–3249

    PubMed  CAS  Google Scholar 

  31. Filippova M, Brown-Bryan TA, Casiano CA, Duerksen-Hughes PJ (2005) The human papillomavirus 16 E6 protein can either protect or further sensitize cells to TNF: effect of dose. Cell Death Differ 12(12):1622–1635

    PubMed  CAS  Google Scholar 

  32. Filippova M, Filippov VA, Kagoda M, Garnett T, Fodor N, Duerksen-Hughes PJ (2009) Complexes of human papillomavirus type 16 E6 proteins form pseudo-death-inducing signaling complex structures during tumor necrosis factor-mediated apoptosis. J Virol 83(1):210–227

    PubMed  CAS  Google Scholar 

  33. Filippova M, Parkhurst L, Duerksen-Hughes PJ (2004) The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J Biol Chem 279(24):25729–25744

    PubMed  CAS  Google Scholar 

  34. Filippova M, Song H, Connolly JL, Dermody TS, Duerksen-Hughes PJ (2002) The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem 277(24):21730–21739

    PubMed  CAS  Google Scholar 

  35. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T (2003) IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4(5):491–496

    PubMed  CAS  Google Scholar 

  36. Frisch M, Biggar RJ, Goedert JJ (2000) Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92(18):1500–1510

    PubMed  CAS  Google Scholar 

  37. Fukushima T, Matsuzawa S, Kress CL, Bruey JM, Krajewska M, Lefebvre S, Zapata JM, Ronai Z, Reed JC (2007) Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor (TRAF)-mediated inflammatory responses. Proc Natl Acad Sci USA 104(15):6371–6376

    PubMed  CAS  Google Scholar 

  38. Garnett TO, Filippova M, Duerksen-Hughes PJ (2006) Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ 13(11):1915–1926

    PubMed  CAS  Google Scholar 

  39. Gaur U, Aggarwal BB (2003) Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 66(8):1403–1408

    PubMed  CAS  Google Scholar 

  40. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82(2):373–428

    PubMed  CAS  Google Scholar 

  41. Gruber T, Hermann-Kleiter N, Hinterleitner R, Fresser F, Schneider R, Gastl G, Penninger JM, Baier G (2009) PKC-theta modulates the strength of T cell responses by targeting Cbl-b for ubiquitination and degradation. Sci Signal 2(76):ra30

    PubMed  Google Scholar 

  42. Guedat P, Colland F (2007) Patented small molecule inhibitors in the ubiquitin proteasome system. BMC Biochem 8(Suppl 1):S14

    PubMed  Google Scholar 

  43. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, Tommasino M (2007) TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178(5):3186–3197

    PubMed  CAS  Google Scholar 

  44. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18(18):2195–2224

    PubMed  CAS  Google Scholar 

  45. Ingham RJ, Gish G, Pawson T (2004) The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene 23(11):1972–1984

    PubMed  CAS  Google Scholar 

  46. Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216

    PubMed  CAS  Google Scholar 

  47. Jiang Z, Mak TW, Sen G, Li X (2004) Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci USA 101(10):3533–3538

    PubMed  CAS  Google Scholar 

  48. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC (1999) The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286(5438):309–312

    PubMed  CAS  Google Scholar 

  49. Johnson ES, Ma PC, Ota IM, Varshavsky A (1995) A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem 270(29):17442–17456

    PubMed  CAS  Google Scholar 

  50. Kanayama A, Seth RB, Sun L, Ea CK, Hong M, Shaito A, Chiu YH, Deng L, Chen ZJ (2004) TAB 2 and TAB 3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 15(4):535–548

    PubMed  CAS  Google Scholar 

  51. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M, Inoue J, Uematsu S, Takeuchi O, Akira S (2004) Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 5(10):1061–1068

    PubMed  CAS  Google Scholar 

  52. Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN (2001) Immunotherapy through TCR gene transfer. Nat Immunol 2(10):957–961

    PubMed  CAS  Google Scholar 

  53. Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, Angstrom T, Dillner J (2000) Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 82(7):1332–1338

    PubMed  CAS  Google Scholar 

  54. Klausner RD, Lippincott-Schwartz J, Bonifacino JS (1990) The T cell antigen receptor: insights into organelle biology. Annu Rev Cell Biol 6:403–431

    PubMed  CAS  Google Scholar 

  55. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347(21):1645–1651

    PubMed  CAS  Google Scholar 

  56. Krappmann D, Scheidereit C (2005) A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways. EMBO Rep 6(4):321–326

    PubMed  CAS  Google Scholar 

  57. Kuhns MS, Davis MM, Garcia KC (2006) Deconstructing the form and function of the TCR/CD3 complex. Immunity 24(2):133–139

    PubMed  CAS  Google Scholar 

  58. Kumar H, Kawai T, Akira S (2009) Toll-like receptors and innate immunity. Biochem Biophys Res Commun 388(4):621–625

    PubMed  CAS  Google Scholar 

  59. Latres E, Chiaur DS, Pagano M (1999) The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 18(4):849–854

    PubMed  CAS  Google Scholar 

  60. Le Bon A, Tough DF (2002) Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 14(4):432–436

    PubMed  CAS  Google Scholar 

  61. Lee TH, Shank J, Cusson N, Kelliher MA (2004) The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem 279(32):33185–33191

    PubMed  CAS  Google Scholar 

  62. Lin CH, Chang HS, Yu WC (2008) USP11 stabilizes HPV-16E7 and further modulates the E7 biological activity. J Biol Chem 283(23):15681–15688

    PubMed  CAS  Google Scholar 

  63. Lin X, Wang D (2004) The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling. Semin Immunol 16(6):429–435

    PubMed  CAS  Google Scholar 

  64. Liu HH, Xie M, Schneider MD, Chen ZJ (2006) Essential role of TAK1 in thymocyte development and activation. Proc Natl Acad Sci USA 103(31):11677–11682

    PubMed  CAS  Google Scholar 

  65. Mammas IN, Sourvinos G, Giannoudis A, Spandidos DA (2008) Human papilloma virus (HPV) and host cellular interactions. Pathol Oncol Res 14(4):345–354

    PubMed  CAS  Google Scholar 

  66. Micheau O, Tschopp J (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114(2):181–190

    PubMed  CAS  Google Scholar 

  67. Miller RL, Meng TC, Tomai MA (2008) The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect 21(2):69–87

    PubMed  CAS  Google Scholar 

  68. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78(21):11451–11460

    PubMed  Google Scholar 

  69. Nalepa G, Rolfe M, Harper JW (2006) Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 5(7):596–613

    PubMed  CAS  Google Scholar 

  70. Oeckinghaus A, Wegener E, Welteke V, Ferch U, Arslan SC, Ruland J, Scheidereit C, Krappmann D (2007) Malt1 ubiquitination triggers NF-kappaB signaling upon T cell activation. EMBO J 26(22):4634–4645

    PubMed  CAS  Google Scholar 

  71. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78(5):773–785

    PubMed  CAS  Google Scholar 

  72. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, Harran P, Wang X (2007) Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12(5):445–456

    PubMed  CAS  Google Scholar 

  73. Petroski MD, Deshaies RJ (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6(1):9–20

    PubMed  CAS  Google Scholar 

  74. Pichlmair A, Reis e Sousa C (2007) Innate recognition of viruses. Immunity 27(3):370–383

    PubMed  CAS  Google Scholar 

  75. Pickart CM (2001) Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503–533

    PubMed  CAS  Google Scholar 

  76. Pomerantz JL, Baltimore D (2002) Two pathways to NF-kappaB. Mol Cell 10(4):693–695

    PubMed  CAS  Google Scholar 

  77. Qiao G, Li Z, Molinero L, Alegre ML, Ying H, Sun Z, Penninger JM, Zhang J (2008) T cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b. Mol Cell Biol 28(7):2470–2480

    PubMed  CAS  Google Scholar 

  78. Richards RM, Lowy DR, Schiller JT, Day PM (2006) Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci USA 103(5):1522–1527

    PubMed  CAS  Google Scholar 

  79. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC (2006) Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 106(6):1316–1319

    PubMed  CAS  Google Scholar 

  80. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487–2498

    PubMed  CAS  Google Scholar 

  81. Rudolph MG, Stanfield RL, Wilson IA (2006) How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 24:419–466

    PubMed  CAS  Google Scholar 

  82. Sato S, Sanjo H, Tsujimura T, Ninomiya-Tsuji J, Yamamoto M, Kawai T, Takeuchi O, Akira S (2006) TAK1 is indispensable for development of T cells and prevention of colitis by the generation of regulatory T cells. Int Immunol 18(10):1405–1411

    PubMed  CAS  Google Scholar 

  83. Sato S, Sugiyama M, Yamamoto M, Watanabe Y, Kawai T, Takeda K, Akira S (2003) Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J Immunol 171(8):4304–4310

    PubMed  CAS  Google Scholar 

  84. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75(3):495–505

    PubMed  CAS  Google Scholar 

  85. Scheffner M, Whitaker NJ (2003) Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 13(1):59–67

    PubMed  CAS  Google Scholar 

  86. Schneider V, Kay S, Lee HM (1983) Immunosuppression as a high-risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytol 27(3):220–224

    PubMed  CAS  Google Scholar 

  87. Scholten KB, Schreurs MW, Ruizendaal JJ, Kueter EW, Kramer D, Veenbergen S, Meijer CJ, Hooijberg E (2005) Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin Immunol 114(2):119–129

    PubMed  CAS  Google Scholar 

  88. Schreurs MW, Scholten KB, Kueter EW, Ruizendaal JJ, Meijer CJ, Hooijberg E (2003) In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J Immunol 171(6):2912–2921

    PubMed  CAS  Google Scholar 

  89. Schulze-Luehrmann J, Ghosh S (2006) Antigen-receptor signaling to nuclear factor kappa B. Immunity 25(5):701–715

    PubMed  CAS  Google Scholar 

  90. Schwartz AL, Ciechanover A (2009) Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 49:73–96

    PubMed  CAS  Google Scholar 

  91. Sen GC (2001) Viruses and interferons. Annu Rev Microbiol 55:255–281

    PubMed  CAS  Google Scholar 

  92. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J (2003) Triggering the interferon antiviral response through an IKK-related pathway. Science 300(5622):1148–1151

    PubMed  CAS  Google Scholar 

  93. Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ (2004) The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 14(3):289–301

    PubMed  CAS  Google Scholar 

  94. Sun SC (2008) Deubiquitylation and regulation of the immune response. Nat Rev Immunol 8(7):501–511

    PubMed  CAS  Google Scholar 

  95. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21:335–376

    PubMed  CAS  Google Scholar 

  96. Tang ED, Wang CY, Xiong Y, Guan KL (2003) A role for NF-kappaB essential modifier/IkappaB kinase-gamma (NEMO/IKKgamma) ubiquitination in the activation of the IkappaB kinase complex by tumor necrosis factor-alpha. J Biol Chem 278(39):37297–37305

    PubMed  CAS  Google Scholar 

  97. Thompson DA, Zacny V, Belinsky GS, Classon M, Jones DL, Schlegel R, Munger K (2001) The HPV E7 oncoprotein inhibits tumor necrosis factor alpha-mediated apoptosis in normal human fibroblasts. Oncogene 20(28):3629–3640

    PubMed  CAS  Google Scholar 

  98. Tungteakkhun SS, Duerksen-Hughes PJ (2008) Cellular binding partners of the human papillomavirus E6 protein. Arch Virol 153(3):397–408

    PubMed  CAS  Google Scholar 

  99. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D (2007) IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131(4):669–681

    PubMed  CAS  Google Scholar 

  100. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J (2007) IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131(4):682–693

    PubMed  CAS  Google Scholar 

  101. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–19

    PubMed  CAS  Google Scholar 

  102. Wan YY, Chi H, Xie M, Schneider MD, Flavell RA (2006) The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat Immunol 7(8):851–858

    PubMed  CAS  Google Scholar 

  103. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412(6844):346–351

    PubMed  CAS  Google Scholar 

  104. Wang L, Du F, Wang X (2008) TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133(4):693–703

    PubMed  CAS  Google Scholar 

  105. Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430(7000):694–699

    PubMed  CAS  Google Scholar 

  106. Wing SS (2003) Deubiquitinating enzymes–the importance of driving in reverse along the ubiquitin-proteasome pathway. Int J Biochem Cell Biol 35(5):590–605

    PubMed  CAS  Google Scholar 

  107. Wu CJ, Ashwell JD (2008) NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation. Proc Natl Acad Sci USA 105(8):3023–3028

    PubMed  CAS  Google Scholar 

  108. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD (2006) Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation. Nat Cell Biol 8(4):398–406

    PubMed  CAS  Google Scholar 

  109. Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP (2003) Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell 11(6):1445–1456

    PubMed  CAS  Google Scholar 

  110. Yamamoto M, Okamoto T, Takeda K, Sato S, Sanjo H, Uematsu S, Saitoh T, Yamamoto N, Sakurai H, Ishii KJ, Yamaoka S, Kawai T, Matsuura Y, Takeuchi O, Akira S (2006) Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat Immunol 7(9):962–970

    PubMed  CAS  Google Scholar 

  111. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301(5633):640–643

    PubMed  CAS  Google Scholar 

  112. Yamamoto M, Sato S, Saitoh T, Sakurai H, Uematsu S, Kawai T, Ishii KJ, Takeuchi O, Akira S (2006) Cutting edge: pivotal function of Ubc13 in thymocyte TCR signaling. J Immunol 177(11):7520–7524

    PubMed  CAS  Google Scholar 

  113. Yang B, Gay DL, MacLeod MK, Cao X, Hala T, Sweezer EM, Kappler J, Marrack P, Oliver PM (2008) Nedd4 augments the adaptive immune response by promoting ubiquitin-mediated degradation of Cbl-b in activated T cells. Nat Immunol 9(12):1356–1363

    PubMed  CAS  Google Scholar 

  114. Yang R, Murillo FM, Delannoy MJ, Blosser RL, WHt Yutzy, Uematsu S, Takeda K, Akira S, Viscidi RP, Roden RB (2005) B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 174(12):7912–7919

    PubMed  CAS  Google Scholar 

  115. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99(25):16168–16173

    PubMed  CAS  Google Scholar 

  116. Youde SJ, Dunbar PR, Evans EM, Fiander AN, Borysiewicz LK, Cerundolo V, Man S (2000) Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res 60(2):365–371

    PubMed  CAS  Google Scholar 

  117. Youde SJ, McCarthy CM, Thomas KJ, Smith KL, Man S (2005) Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. Int J Cancer 114(4):606–612

    PubMed  CAS  Google Scholar 

  118. Yuan H, Fu F, Zhuo J, Wang W, Nishitani J, An DS, Chen IS, Liu X (2005) Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis. Oncogene 24(32):5069–5078

    PubMed  CAS  Google Scholar 

  119. Zhou H, Wertz I, O’Rourke K, Ultsch M, Seshagiri S, Eby M, Xiao W, Dixit VM (2004) Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 427(6970):167–171

    PubMed  CAS  Google Scholar 

  120. Zhou Q, Mrowietz U, Rostami-Yazdi M (2009) Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med 47(7):891–905

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We apologize to the many authors whose publications are not cited directly because of space limitations. This work is supported by grants from National Natural Science Foundation of China (No. 81071302).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Dermatology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 Qingchun Road East, Hangzhou, 310016, People’s Republic of China

    Qiang Zhou, Kejian Zhu & Hao Cheng

Authors
  1. Qiang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kejian Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hao Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hao Cheng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhou, Q., Zhu, K. & Cheng, H. Ubiquitination in host immune response to human papillomavirus infection. Arch Dermatol Res 303, 217–230 (2011). https://doi.org/10.1007/s00403-011-1141-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-011-1141-0

Keywords

Search

Navigation